



LYMPHOID NEOPLASIA

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

Miguel A. Galindo-Campos,^{1,*} Nura Lutfi,^{1,*} Sarah Bonnin,² Carlos Martínez,³ Talia Velasco-Hernandez,^{4,5} Violeta García-Hernández,¹ Juan Martín-Caballero,⁶ Coral Ampurdanés,¹ Ramón Gimeno,⁷ Lluís Colomo,⁸ Gaël Roué,⁴ Guillaume Guilbaud,⁹ Françoise Dantzer,¹⁰ Pilar Navarro,¹¹⁻¹³ Matilde Murga,¹⁴ Oscar Fernández-Capetillo,^{14,15} Anna Bigas,^{1,4,16} Pablo Menéndez,^{4,5,16,17} Julian E. Sale,⁹ and José Yélamos^{1,7}

¹Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; ²Center for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain; ³Experimental Pathology Unit, Instituto Murciano de Investigación Biosanitaria–Laboratorio de Investigación Biosanitaria–Arrixaca, Murcia, Spain; ⁴Josep Carreras Leukemia Research Institute, Barcelona, Spain; ⁵Instituto de Salud Carlos III (ISCIII), Redes de Investigación Cooperativa Orientadas a Resultados en Salud, Madrid, Spain; ⁶Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain; ⁷Laboratory of Immunology, Department of Pathology; ⁸Department of Pathology, Hospital del Mar, Barcelona, Spain; ⁹Division of Protein and Nucleic Acid Chemistry, Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom; ¹⁰Biotechnology and Cell Signaling, Unité Mixte de Recherche (UMR) 7242 Centre National de la Recherche Scientifique, Laboratory of Excellence Medalis, École Supérieure de Biotechnologie de Strasbourg, Strasbourg University, Illkirch, France; ¹¹Institute of Biomedical Research of Barcelona (IBB)–CSIC, Barcelona, Spain; ¹²Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, Spain; ¹³Hospital del Mar Medical Research Institute, Unidad Asociada IBB-CSIC, Barcelona, Spain; ¹⁴Genomic Instability Group, Spanish National Cancer Research Centre, Madrid, Spain; ¹⁵Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden; ¹⁶ISCIII, Centro de Investigación Biomédica en Red de Oncología, Barcelona, Spain; and ¹⁷Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain

KEY POINTS

- **PARP-2 deficiency prevents c-Myc-driven B-cell lymphoma progression, whereas PARP-1 deficiency accelerates lymphomagenesis.**
- **PARP-2 limits replication stress of c-Myc-overexpressing B cells and promotes cell survival, whereas PARP-1 affects regulatory T cells.**

Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the E μ -Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic E μ -Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors.

Introduction

Poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 catalytically cleave β -NAD⁺ to transfer ADP-ribose moieties onto amino acid residues of proteins, creating long chains of poly (ADP-ribose) (PARylation).^{1,2} PARP-1, PARP-2, and PARylation play a central role in DNA repair, particularly in single-strand breaks, and mice lacking either enzyme display disturbances in the DNA damage response (DDR).^{3,4} Considering the critical role of DDR in tumor development and progression, PARP inhibitors have emerged as an important new class of therapeutics in cancer.^{5,6}

However, PARP inhibitors currently in clinical trials or approved for clinical use⁵ are still unable to discriminate between individual PARP proteins, despite increasing evidence suggesting that PARP-1 and PARP-2 have discrete biologic roles. For instance, PARP-2, but not PARP-1, has been implicated in processes characterized by rapid proliferation, including spermatogenesis,⁷ T-cell development,^{8,9} and hematopoiesis.¹⁰ Furthermore, PARP-2, but not PARP-1, limits replication stress during erythropoiesis.¹¹ A similar bias toward pathologies associated with tissues exhibiting a high rate of proliferation has also been

reported in other mouse models, with a compromised response to replication stress.¹²

Replication stress, characterized by slowing or stalling of replication fork progression,¹³ initiates a signaling cascade that protects the arrested replication forks from breakage while simultaneously activating cytostatic or cytotoxic responses, which limit the expansion of the damaged cells.¹³ Dysregulated expression of oncogenes, such as c-Myc, is a key source of replication stress leading to tumor development.¹⁴ c-Myc dysregulation occurs in a wide variety of hematologic malignancies, including large B-cell lymphoma, lymphoblastic lymphoma, and multiple myeloma, and its overexpression has been linked to aggressiveness and poor prognosis.^{15,16} We examined how specific PARP-1 or PARP-2 deficiencies affect c-Myc-driven B-cell lymphoma development. We used the E μ -Myc mouse model, in which the c-Myc gene driven by the immunoglobulin H enhancer results in tumor development that mimics human Burkitt lymphoma.¹⁷ c-Myc overexpression in the E μ -Myc mouse model results in high proliferation of bone marrow (BM) pre-B cells associated with activation of cell death pathways to control homeostasis.¹⁷ However, the appearance of replication stress-associated mutations that block cell death leads to the development of B-cell lymphoma, a process that occurs between 4 to 7 months of age.^{18,19}

In this study, we found that PARP-1 and PARP-2 exert distinct and opposing effects on the development of c-Myc-driven B-cell lymphoma in mice. Loss of PARP-2, but not loss of PARP-1, exacerbates E μ -Myc-driven replication stress in preleukemic pre-B cells, resulting in the accumulation of DNA damage and concomitant cell death, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells (Tregs) that may contribute to an acceleration of tumorigenesis. By elucidating the specific role of PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma, our results provide crucial information that has implications for the development of PARP inhibition-based therapies, highlighting the need to use selective PARP-2 inhibitors in the treatment of c-Myc-driven tumors.

Methods

Mice

Parp-1^{-/-}, Parp-2^{-/-}, Cd19-creParp-2^{fl/fl}, and E μ -Myc transgenic mice have been described elsewhere.²⁰⁻²³ p53^{-/-} mice were from The Jackson Laboratory. B6.SJL-ptprcPep3 mice were from Charles River Laboratories. Mice breeding strategies, genotyping, treatments, and generation of an acute T-cell acute lymphoblastic leukemia (T-ALL) mouse model are detailed in the data supplement. All mice had a C57BL/6J background and were reared under pathogen-free conditions. The Barcelona Biomedical Research Park Institutional Animal Care and Use Committee approved the studies, and all experiments were performed in accordance with relevant guidelines and regulations.

Cell lines and viability assay

Cell lines, selective PARP-2 inhibitor treatment, and viability assay are described in the supplemental Data (available on the *Blood* Web site).

Whole-blood analysis and histology

Peripheral blood was collected in EDTA and analyzed using a CVM Procell Vet Haematology Blood Analyzer. Histology details are indicated in the data supplement.

Flow cytometry and cell sorting

BM, lymph node, and spleen cell suspensions were washed in phosphate-buffered saline and resuspended in phosphate-buffered saline containing 0.5% bovine serum albumin. Immunostaining, cell acquisition, and analysis details of flow cytometry and cell sorting are available in the data supplement.

Immunofluorescence microscopy and comet assay

Immunofluorescence microscopy and alkaline comet assay on sorted BM pre-B cells was performed as indicated in the data supplement.

BrdU incorporation

Mice received a single intraperitoneal injection of 5-bromo-2'-deoxyuridine (BrdU; BD Biosciences; 1 mg/6 g mouse weight) at 2 hours before euthanasia. Cells were surface stained, fixed, permeabilized, and intracellularly stained using a BrdU Flow Kit (BD Biosciences).

Western blot

Western blot was performed as described in the supplemental Data.

Gene expression

Total RNA isolation, RNA sequencing (RNAseq), and quantitative reverse transcription polymerase chain reaction were performed as indicated in the data supplement. RNAseq data have been deposited into the Gene Expression Omnibus under accession #GSE144050.

Statistical analysis

Data are presented as mean \pm standard error of the mean (SEM). The log-rank test was used to determine the significance of animal survival. All other statistical analyses used a Mann-Whitney test. Values of $P < .05$ were considered significant. Bioinformatic statistical analysis of RNAseq data is indicated in the supplemental Data.

Results

Loss of PARP-2 prevents c-Myc-induced B-cell lymphoma, whereas loss of PARP-1 accelerates tumorigenesis in mice

To evaluate the specific functions of PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma, we crossed either Parp-2^{-/-} or Parp-1^{-/-} mice with E μ -Myc transgenic mice and followed spontaneous tumor development for 500 days. Only mice with the c-Myc transgene, inherited paternally, in heterozygous configuration (E μ -Myc^{T/+}) were used in these studies. Comparison of Kaplan-Meier tumor-free survival curves showed that loss of both alleles of *Parp-2* in E μ -Myc mice significantly reduced the incidence of B-cell lymphoma (35% remained lymphoma free vs 6% tumor-free control mice) and enhanced the latency compared with control E μ -Myc mice (median survival age, 326 vs 127 days; Figure 1A-B). Meanwhile, loss of only 1 allele of *Parp-2* did not affect the tumor latency of E μ -Myc mice (data not shown). PARP-2




Figure 1. Oposing roles of PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma. (A) Kaplan-Meier curves comparing B-cell lymphoma-free survival of $E\mu$ -Myc^{T/+}, $E\mu$ -Myc^{T/+}Parp-1^{-/-}, and $E\mu$ -Myc^{T/+}Parp-2^{-/-} mice. Survival was monitored for 500 days. (B) Representation of the median and 25th and 75th percentile survival periods of $E\mu$ -Myc^{T/+}, $E\mu$ -Myc^{T/+}Parp-1^{-/-}, and $E\mu$ -Myc^{T/+}Parp-2^{-/-} mice. (C) Quantitative reverse transcription polymerase chain reaction analysis of *c-Myc* gene expression in BM pre-B cells. Samples were normalized according to β -actin expression levels. Results are expressed as log₂-fold expression compared with levels measured in wild-type (WT) cells. Values represent mean \pm SEM obtained from 3 independent experiments. (D) Representative flow cytometric dot plots showing pre-B, immature, and mixed B-cell lymphomas. (E) Bar plot showing the percentage of pre-B, immature, and mixed B-cell lymphoma tumors in each genotype. (F-G) Representation of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive (TUNEL⁺) (F) and Ki67⁺ (G) cells in tumors from the indicated genotypes. Values represent mean \pm SEM for 10 randomly selected fields. **P* < .05, ***P* < .01, ****P* < .001. Ig, immunoglobulin.

deficiency only in B cells²³ also delayed lymphoma development in $E\mu$ -Myc mice, suggesting that the lymphoma-promoting role of PARP-2 is due to an intrinsic effect on B cells (supplemental Figure 1). Interestingly, the protection conferred by loss of PARP-2 on $E\mu$ -Myc-driven tumor formation was not observed after deletion of PARP-1. Rather, $E\mu$ -Myc^{T/+}Parp-1^{-/-} mice developed terminal lymphoma earlier (median survival age, 90 days) than control $E\mu$ -Myc mice (Figure 1A-B). As expected, we did not detect B-cell lymphoma in either PARP-2- or PARP-1-deficient mice in the absence of *c-Myc* overexpression (data not shown). Importantly, the absence of either PARP-2 or PARP-1 did not modify the expression of *c-Myc* in $E\mu$ -Myc BM pre-B cells (Figure 1C).

Flow cytometric characterization of PARP-2-deficient tumors revealed that there were no differences in the frequency of pre-B lymphoma or B lymphoma (immature plus mixed) compared with those observed in $E\mu$ -Myc control and $E\mu$ -Myc^{T/+}Parp-1^{-/-} mice (Figure 1D-E). Hematoxylin and eosin staining also revealed similar infiltration of malignant B cells in nonlymphoid organs such as liver, lung, and kidney in $E\mu$ -Myc mice in the presence or absence of either PARP-1 or PARP-2 (supplemental Figure 2A). However, B-cell lymphoma in $E\mu$ -Myc^{T/+}Parp-2^{-/-} mice showed statistically significant higher levels of cell death, detected by TUNEL assay (Figure 1F; supplemental Figure 2B), and lower proliferation, detected by Ki67 staining, than tumors from $E\mu$ -Myc^{T/+}Parp-1^{-/-} and $E\mu$ -Myc control mice (Figure 1G; supplemental Figure 2C).

To determine whether loss of PARP-2 or PARP-1 has an effect on other models of leukemia, we studied their impact on survival in a T-ALL model. Our results indicate that neither PARP-1 deficiency nor PARP-2 deficiency influenced the survival in a mouse model of Notch-1-mediated T-ALL (supplemental Figure 3), suggesting the effect may be specific to *c-Myc*-driven B-cell lymphoma.

PARP-2 is required for c-Myc-driven expansion of preleukemic pre-B cells

To further determine the mechanisms underlying the protective effect of PARP-2 deficiency on *c-Myc*-driven lymphomagenesis, we analyzed preleukemic B cells in BM from tumor-free 4-week-old mice. Overall, BM cellularity was not altered in $E\mu$ -Myc mice compared with wild-type mice as previously described.²⁴ However, in $E\mu$ -Myc mice, a significant decrease in total BM cells was observed in the absence of PARP-2, whereas PARP-1 deficiency significantly increased total BM cell number (Figure 2). As expected, at this pretumoral stage, the BM of $E\mu$ -Myc^{T/+} mice displayed a significant expansion of the pre-B cell compartment and a concomitant reduction of immature B cell numbers compared with nontransgenic control mice. Interestingly, PARP-2 deficiency significantly reduced the expansion of the pre-B cell compartment induced by *c-Myc* overexpression, whereas PARP-1 deficiency increased the expansion of pre-B cells (Figure 2A-B). A slight reduction in pre-B cells was also observed in the spleen of $E\mu$ -Myc^{T/+}Parp-2^{-/-} compared with $E\mu$ -Myc^{T/+} control and $E\mu$ -Myc^{T/+}Parp-1^{-/-} mice. Neither PARP-1 nor PARP-2 deficiency modified the marginal zone or follicular B-cell population in $E\mu$ -Myc mice (Figure 2C-D).

Peripheral blood analysis also revealed that PARP-2 deficiency, but not loss of PARP-1, mitigated the expansion of the white blood cell compartment in young preleukemic $E\mu$ -Myc mice (supplemental Figure 4A), mainly at the level of preventing the expansion of pre-B cells (supplemental Figure 4B).

Altogether, these results suggest that PARP-2 favors the earliest stages of transformation initiated by *c-Myc* overexpression in pre-B cells.




Figure 2. PARP-2 is required for c-Myc-driven expansion of preleukemic pre-B cells. (A) Representative flow cytometric density plots showing pre-B ($CD19^+B220^+c\text{-kit}^-IgD^-IgM^-$), immature ($CD19^+B220^+c\text{-kit}^-IgD^-IgM^+$), and mature ($CD19^+B220^+c\text{-kit}^-IgD^+IgM^+$) BM B cells from mice of the indicated genotypes. Percentage of cells in the individual subpopulations with regard to each gate is indicated in each quadrant. Values represent the mean of ≥ 8 mice of each genotype. (B) Bar plot displaying total number of BM cells and absolute number of pre-B, immature (ImmB), and mature (MatB) BM B cells. The number of cells in each population was calculated by multiplying the percentage of each population by the total number of BM cells. (C) Representative flow cytometric density plots showing pre-B ($CD19^+B220^+c\text{-kit}^-IgD^-IgM^-$), marginal zone (MZ; $CD19^+B220^+c\text{-kit}^-CD21^{high}CD23^{low}$), and follicular (FO) B cells ($CD19^+B220^+c\text{-kit}^-CD21^{low}CD23^{high}$) from spleens of mice of the indicated genotypes. Percentage of cells in the individual subpopulations with regard to each gate is indicated in each quadrant. Values represent the mean of ≥ 8 mice of each genotype. (D) Bar plot showing total number of spleen cells and the absolute number of pre-B, MZ, and FO B cells. The number of cells in each population was calculated by multiplying the percentage of each population by the total number of splenocytes. Values represent mean \pm SEM of ≥ 8 mice of each genotype. Only *P* values between groups either containing or not the *EμMyc* transgene are represented in the graph for clarity. **P* < .05, ***P* < .01. Ig, immunoglobulin; WT, wild type.




Figure 3. PARP-2 mitigates DNA damage accumulation in preleukemic E μ -Myc pre-B cells. (A) Representative flow cytometric staining profiles of γ H2AX in BM pre-B cells derived from mice of the indicated genotypes. (B) Graph depicting the percentage of positive γ H2AX cells. Bars represent mean \pm SEM obtained from \geq 5 mice per genotype. (C) Representative microscopic images depicting immunofluorescence staining of γ H2AX in fixed BM pre-B cells. Microscopy was performed by using a Leica TCS SP5 confocal microscope. Red indicates γ H2AX; blue indicates DAPI. Original magnification: $\times 63$. (D) High-throughput microscopy of γ H2AX levels per individual nucleus. At least 2000 nuclei were quantified per condition. Horizontal lines represent median values for each genotype. (E) Graph depicting the percentage of cells showing a pannuclear distribution of γ H2AX. (F) Representative images showing DNA damage in BM pre-B cells, visualized by alkaline comet assay, from mice of the indicated genotypes. Original magnification: $\times 10$. (G) Graph showing the percentage of pre-B cells with comet. An average of 100 cells was scored for each genotype. Bars represent mean \pm SEM obtained from 3 mice per genotype from independent experiments. * $P < .05$, ** $P < .01$. a.u., arbitrary units; WT, wild type.

Transcriptome analysis of preleukemic E μ -Myc BM pre-B cells

To gain further insights into the distinct roles of PARP-1 and PARP-2 in the development of Myc-driven B-cell lymphoma, we performed transcriptomic analysis of purified BM pre-B cells from 4-week-old tumor-free E μ -Myc^{T/+} wild-type, E μ -Myc^{T/+} Parp-1^{-/-}, and E μ -Myc^{T/+}Parp-2^{-/-} mice. Bioinformatic analyses showed that, with a false discovery rate cutoff of 1%, 53 genes were upregulated and 72 genes were downregulated in E μ -Myc^{T/+}Parp-2^{-/-} compared with E μ -Myc^{T/+} control pre-B cells. In contrast, as many as 1191 genes were upregulated and 1334 genes were downregulated in E μ -Myc^{T/+}Parp-1^{-/-} compared with E μ -Myc^{T/+} control pre-B cells (supplemental Tables 1-4).

Gene set enrichment analysis (GSEA) showed that PARP-2 deficiency resulted in an enrichment of pathways involved in the DDR, including DNA replication, ATR pathway, DNA repair, G2/M checkpoints, cell cycle mitotic and intrinsic apoptotic signaling pathways (supplemental Figure 5). In contrast, PARP-1 deficiency led to an enrichment of

chemotaxis, inflammatory response, and transforming growth factor β (Tgfb1) receptor binding pathways (supplemental Figures 5 and 6).

PARP-2 mitigates DNA damage accumulation in preleukemic E μ -Myc BM pre-B cells

The enrichment of pathways involved in the DDR in preleukemic BM pre-B cells observed in E μ -Myc^{T/+}Parp-2^{-/-} mice suggests an accumulation of DNA damage. Accordingly, we monitored the phosphorylation of histone H2AX (γ H2AX), a sensitive indicator of DNA injury.²⁵ Preleukemic BM pre-B cells from E μ -Myc^{T/+}Parp-2^{-/-} mice exhibited increased phosphorylation of H2AX compared with control E μ -Myc and E μ -Myc^{T/+}Parp-1^{-/-} pre-B cells (Figure 3A-B). The increase in γ H2AX was mainly localized in S/G2 cells, suggesting replication stress.^{26,27} These results were confirmed by immunostaining of γ H2AX and immunofluorescence microscopy (Figure 3C-D). Notably, pre-B cells from E μ -Myc^{T/+}Parp-2^{-/-} mice displayed a significantly higher percentage of cells with pannuclear γ H2AX staining, characteristic of replication stress,²⁸ than control E μ -Myc and E μ -Myc^{T/+}Parp-1^{-/-} pre-B cells (Figure 3C,E). We next subjected BM pre-B cells to an




Figure 4. DNA break repair in preleukemic BM pre-B cells. (A) Kinetics of H2AX phosphorylation after irradiation (1 Gy) in BM pre-B cells from preleukemic $E\mu$ -Myc^{T/+}, $E\mu$ -Myc^{T/+}Parp-2^{-/-}, and $E\mu$ -Myc^{T/+}Parp-1^{-/-} mice. (B-D) Representative microscopic images showing immunofluorescence staining of Rad51 (B), 53BP1 (C), and phospho-RPA (pRPA) (D) foci in BM pre-B cells derived from mice of the indicated genotype (left) and high-throughput microscopy of Rad51 (B), 53BP1 (C), and pRPA (D) fluorescence levels per individual nucleus (right). Red indicates Rad51 or 53BP1 or pRPA; blue indicates 4',6-diamidino-2-phenylindole. At least 2000 nuclei were quantified per condition. Horizontal lines represent median values for each genotype. Original magnification: $\times 63$. (E) Representative flow cytometric dot plots of phosphorylated Chk-1 (pChk-1) in BM pre-B cells of each genotype. (F) Graph showing the percentage of pChk-1⁺ cells in different cell cycle phases. Bars represent mean \pm SEM obtained from at least 6 mice per genotype. (G-H) Large-scale gene expression and GSEA showed a significant enrichment for DNA replication (G) and ATR (H) pathways in pre-B cells from $E\mu$ -Myc^{T/+}Parp-2^{-/-} mice compared with $E\mu$ -Myc^{T/+} wild-type (WT) control cells. At the top is the GSEA enrichment plot; at the bottom, the normalized gene expression heatmap of genes involved in those pathways. * $P < .05$, ** $P < .01$, *** $P < .001$. a.u., arbitrary units.

alkaline comet assay to assess induction and repair of DNA breaks independently of their signaling and processing markers. We observed a significant increase in $E\mu$ -Myc^{T/+}Parp-2^{-/-} pre-B cells displaying a comet shape compared with control $E\mu$ -Myc and $E\mu$ -Myc^{T/+}Parp-1^{-/-} pre-B cells (Figure 3F-G).

The accumulation of DNA damage in PARP-2-deficient $E\mu$ -Myc B cells could stem from impaired DNA strand break repair, increased generation of intrinsic DNA damage, or both. Accordingly, to measure DNA break repair, we monitored the kinetics of H2AX phosphorylation after irradiation (1 Gy) in pre-B cells from preleukemic mice cultured on MS-5 stromal cells in the presence of recombinant interleukin-7. Although both $E\mu$ -Myc^{T/+}Parp-2^{-/-} and control $E\mu$ -Myc cells displayed a similar decay of γ H2AX signal over time, deficiency of PARP-1 delayed loss of γ H2AX (Figure 4A), consistent with ineffective DNA strand break repair in the absence of PARP-1 but not in

the absence of PARP-2. Furthermore, we analyzed the total nuclear fluorescence intensity of RAD51 and 53BP1 foci in preleukemic BM pre-B cells as markers of homologous recombination and nonhomologous end joining pathways, respectively. A slight increase in RAD51 staining was observed in $E\mu$ -Myc^{T/+}Parp-2^{-/-} with respect to control $E\mu$ -Myc cells, whereas RAD51 staining was decreased in $E\mu$ -Myc^{T/+}Parp-1^{-/-} pre-B cells (Figure 4B). We also observed an increase in 53BP1 staining in $E\mu$ -Myc pre-B cells deficient in PARP-2 with respect to control cells and those deficient in PARP-1 (Figure 4C).

Of note, we also observed an increased level of replication protein A (RPA) phosphorylation on S4/S8 (Figure 4D), triggered by ATM and DNA-PK kinases in response to replication stress,²⁹ in PARP-2-deficient $E\mu$ -Myc pre-B cells compared with the other 2 genotypes. In addition, we monitored the phosphorylation status of Chk1 on S345, a target of ATR, that coordinates the




Figure 5. Effect of PARP-2 and PARP-1 deficiency on $E\mu$ -Myc BM pre-B cell proliferation, cell cycle, and apoptosis. (A-B) In vivo BM pre-B cell proliferation was determined by intraperitoneal injection of 5-week-old mice of the indicated genotypes with BrdU (1 mg/6 g mouse weight). BM cells were harvested at 2 hours after the onset of injection, and BrdU incorporation on pre-B cells was analyzed by flow cytometry. Representative histograms (A) from 2 independent experiments including ≥ 2 mice from each genotype are shown. Numbers indicate percentage of proliferating (BrdU⁺) cells. (B) Bars represent mean \pm SEM (SEM) values of the percentage of BrdU⁺ cells. (C) Representative flow cytometric dot plots showing the cell cycle status of BM pre-B cells in mice from the indicated genotypes. BM pre-B cells were stained with Ki67 to identify cycling cells and 4',6-diamidino-2-phenylindole to measure DNA content. The percentage of cells in each quadrant represents the mean from ≥ 6 mice in each group. (D) Graph showing the percentage of BM pre-B cells for each genotype that are in G₀, G₁, S, and G₂/M phases of the cell cycle. (E-F) Large-scale gene expression and GSEA showed a significant enrichment for G₂/M checkpoint (E) and intrinsic apoptotic signaling (F) pathways in pre-B cells from $E\mu$ -Myc^{T/+}Parp-2^{-/-} mice compared with $E\mu$ -Myc^{T/+} wild-type (WT) control cells. At the left is the GSEA enrichment plot; at the right, the normalized gene expression heatmap of genes involved in that pathways. (G) Representative dot plots showing active caspase-3 staining in BM pre-B cells for each genotype. (H) Bars represent the percentage of cells positive for active caspase-3. Values represent mean \pm SEM obtained from ≥ 6 mice per genotype. (I) Quantitative reverse transcription polymerase chain reaction analysis in BM pre-B cells of genes involved in cell cycle and apoptosis. Samples were normalized according to β -actin expression levels. Results are expressed as fold expression compared with levels measured in WT cells. Values represent mean \pm SEM obtained from 3 independent experiments. * $P < .05$, ** $P < .01$, *** $P < .001$.

response to replication stress.³⁰ This revealed an increased percentage of pChk1⁺ pre-B cells, mainly at the S/G₂/M phase of the cell cycle, from PARP-2-deficient $E\mu$ -Myc mice compared with $E\mu$ -Myc control and $E\mu$ -Myc^{T/+}Parp-1^{-/-} pre-B cells (Figure 4E-F). Accordingly, GSEA showed an enrichment of DNA replication and ATR pathways in the absence of PARP-2 (Figure 4G-H).

Together, our data indicate that DNA strand break repair pathways are not significantly compromised in the absence of PARP-2 in $E\mu$ -Myc pre-B cells. Most likely, the PARP-2 deficiency leads to elevated single-strand breaks, which are rapidly converted to double-strand breaks (DSB) in the S phase instead of a decrease in DSB repair per se.

PARP-2 attenuates the death of preleukemic B cells overexpressing c-Myc

DNA damage activates cytostatic and cytotoxic responses, which limit the expansion of the damaged cells. One or both of these responses may be responsible for the reduced c-Myc-driven expansion of the BM pre-B cell compartment observed in the absence of PARP-2. To evaluate cell proliferation, mice were treated with a single intraperitoneal injection of BrdU for 2 hours. Proliferating BrdU⁺ pre-B cells from the BM of $E\mu$ -Myc^{T/+}Parp-2^{-/-} mice were slightly increased, whereas control $E\mu$ -Myc and $E\mu$ -Myc^{T/+}Parp-1^{-/-} mice exhibited comparable frequencies of BrdU⁺ pre-B cells (Figure 5A-B). We also evaluated the cell cycle status in BM pre-B cells by Ki67 staining to identify cycling cells and 4',6-diamidino-2-phenylindole to




Figure 6. p53 haploinsufficiency abolishes the protective effect of PARP-2 deficiency in the development of B lymphomas in Eμ-Myc^{T/+} mice. (A) Kaplan-Meier curves comparing B-cell lymphoma-free survival of Eμ-Myc^{T/+}Parp-2^{+/+}p53^{+/-} and Eμ-Myc^{T/+}Parp-2^{-/-}p53^{+/-} mice. (B) Bar graph displaying absolute number of total, pre-B, immature (ImmB), and mature (MatB) BM B cells in Eμ-Myc^{T/+}Parp-2^{+/+}p53^{+/-} and Eμ-Myc^{T/+}Parp-2^{-/-}p53^{+/-} mice. (C) Graph showing the percentage of BM pre-B cells for each genotype in G₀, G₁, S, and G₂/M phases of the cell cycle. (D) Bar graph showing the percentage of cells positive for active caspase-3 for each genotype. Values represent mean ± SEM obtained from at least 6 mice per genotype.

measure the amount of DNA content, which distinguishes G₀, G₁, S, and G₂/M phases of the cell cycle. A significant increase of Eμ-Myc^{T/+}Parp-2^{-/-} pre-B cells were found in S phase of the cell cycle as compared with control Eμ-Myc and Eμ-Myc^{T/+}Parp-1^{-/-} pre-B cells (Figure 5C-D). Of note, GSEA on purified Eμ-Myc^{T/+}Parp-2^{-/-} BM pre-B cells showed enrichment for G₂/M checkpoint pathway compared with Eμ-Myc^{Tg/+} control pre-B cells (Figure 5E). Together, these data reveal an S/G₂/M arrest in Eμ-Myc^{T/+}Parp-2^{-/-} compared with control Eμ-Myc pre-B cells, which may be reminiscent of increased replication stress in the absence of PARP-2.

In addition, GSEA showed an enrichment of the intrinsic apoptotic signaling pathway in the absence of PARP-2 (Figure 5F). Accordingly, Eμ-Myc^{T/+}Parp-2^{-/-} BM pre-B cells exhibited a significantly higher percentage of active caspase-3⁺ cells than pre-B cells from either Eμ-Myc^{T/+} control or Eμ-Myc^{T/+}Parp-1^{-/-} mice, indicating increased apoptosis (Figure 5G-H). Quantitative reverse transcription polymerase chain reaction showed expression level changes in genes involved in cell cycle and apoptosis, including p53-dependent genes (Ccnb1ip1, p21, Rb1, Bcl2, Puma), on purified Eμ-Myc^{T/+}Parp-2^{-/-} preleukemic BM pre-B cells compared with Eμ-Myc^{Tg/+} control pre-B cells (Figure 5I).

c-Myc-driven B-cell lymphoma arises once other mutations, often affecting p53, overcome the ability of c-Myc to induce apoptosis. Of note, mutations in *Trp53*, indicated by high p53 expression, were observed in B-cell lymphoma from Eμ-Myc^{T/+} control and Eμ-Myc^{T/+}Parp-2^{-/-} mice (supplemental Figure 7).

p53 haploinsufficiency overcomes the delay in c-Myc-driven B-cell lymphoma development caused by loss of PARP-2

The involvement of p53-mediated pathways in c-Myc-driven lymphoma is well established as deficiency of 1 allele of p53 accelerates the development of B-cell lymphoma in the Eμ-Myc^{T/+} model.³¹ To address whether the delay in c-Myc-driven lymphoma in PARP-2-deficient mice was p53 dependent, we incorporated p53 haploinsufficiency into the crosses to address the epistatic relationship between p53 haploinsufficiency and PARP-2 deficiency. The median survival of 37 days observed in Eμ-Myc^{T/+}Parp-2^{+/+}p53^{+/-} mice was similar to the median survival of 39 days found in Eμ-Myc^{T/+}Parp-2^{-/-}p53^{+/-} mice (Figure 6A), suggesting that protection against B-cell lymphoma development mediated by PARP-2 deficiency takes place in a p53-dependent manner. Of note, p53 haploinsufficiency in Eμ-Myc^{T/+}Parp-2^{-/-} mice restored BM B cell number, avoided S/G₂/M arrest, and reduced apoptosis to similar levels found in Eμ-Myc^{T/+}Parp-2^{+/+}p53^{+/-} control mice (Figure 6B-D). Similarly, the changes of cell cycle- and apoptosis-related genes observed in pre-B cells from Eμ-Myc^{T/+}Parp-2^{-/-} mice relative to Eμ-Myc^{T/+} control mice were no longer observed between pre-B cells from Eμ-Myc^{T/+}Parp-2^{-/-}p53^{+/-} mice and Eμ-Myc^{T/+}Parp-2^{+/+}p53^{+/-} mice (supplemental Figure 8).

Together, our data suggest that PARP-2 deficiency triggers, in response to DNA damage accumulation, a p53-dependent DNA damage response, resulting in cell cycle arrest and impaired survival of c-Myc-overexpressing pre-B cells as the major intrinsic tumor-suppressor mechanism in Eμ-Myc^{T/+}Parp-2^{-/-} mice.




Figure 7. Increased Tregs in preleukemic and tumor-bearing Eμ-Myc^{T/+}Parp-1^{-/-} mice. (A) Representative flow cytometric density plots showing Tregs (CD3⁺CD4⁺CD25⁺FoxP3⁺). (B) Bar plot displaying the frequency of Tregs in preleukemic and lymphoma-infiltrated spleens and lymph nodes of mice of the indicated genotype. Values represent mean ± SEM of at least 6 mice of each genotype. (C) Immunohistochemical staining for FoxP3 of lymphoma-infiltrated lymph nodes of the indicated genotypes. (D) Quantification of FoxP3⁺ infiltrating cells determined by microscopic analysis. (E) Quantitative reverse transcription polymerase chain reaction analysis of *Tgfb1* gene expression in BM pre-B cells. Samples were normalized according to β-actin expression levels. **P* < .05, ***P* < .01, ****P* < .001.

PARP-2 inhibition impairs the proliferation of established human B-cell lymphoma cell lines

To determine whether the growth of established c-Myc-driven B-cell lymphoma is dependent on PARP-2 function, we treated a panel of 4 established human B-cell lymphoma cell lines (SU-DHL-10, SU-DHL-5, DoHH-2, and OCI-Ly3) with increasing doses of a selective PARP-2 inhibitor (UPF-1069).³² We found that this compound inhibited the proliferation of the 4 tested cell lines in a dose-dependent manner (supplemental Figure 9A). This indicates that the growth of frank human B-cell lymphoma with rearranged *Myc* gene is in fact dependent on PARP-2 function, demonstrating the effectiveness of selective PARP-2 inhibitors for therapeutic purposes in c-Myc-driven B-cell lymphoma. In addition, we found that genetic loss of PARP-2, but not PARP-1 (supplemental Figure 9B), led to reduces proliferation of SU-DHL-10 cells (supplemental Figure 9C).

Increased Tregs in lymphoma-infiltrated spleen and lymph node of diseased Eμ-Myc^{T/+}Parp-1^{-/-} mice

Previous work has demonstrated that Tregs suppress antitumor response in endogenous B-cell lymphoma.³³ Accordingly, we analyzed the frequency of Tregs in preleukemic and tumor-infiltrated spleens and lymph nodes of diseased Eμ-Myc^{T/+}, Eμ-Myc^{T/+}Parp-2^{-/-}, and Eμ-Myc^{T/+}Parp-1^{-/-} mice. In preleukemic spleens, we observed an increased frequency of Tregs in Eμ-Myc^{T/+}Parp-1^{-/-} mice compared with Eμ-Myc^{T/+} mice, in agreement with previous results found in Parp-1^{-/-} mice.^{34,35} Flow cytometric analysis revealed an even greater increase in frequency of Tregs in lymphoma-infiltrated spleens and lymph nodes from Eμ-Myc^{T/+}Parp-1^{-/-} mice compared with Eμ-Myc^{T/+} control and Eμ-Myc^{T/+}Parp-2^{-/-} mice (Figure 7A-B). These results were confirmed by immunostaining of FoxP3⁺ and microscopic analysis in tumor-infiltrated lymph

nodes of diseased mice (Figure 7C-D). Interestingly, we observed an increased expression of *Tgfb1*, which has been demonstrated to promote the induction of Tregs,³⁶ in $E\mu$ -Myc^{T/+}Parp-1^{-/-} compared with control and $E\mu$ -Myc^{T/+}Parp-2^{-/-} B cells (Figure 7E; supplemental Figure 6). Our results suggest that increased levels of Tregs in $E\mu$ -Myc^{T/+}Parp-1^{-/-} mice could block the immune response to B-cell lymphoma and thus contribute, at least in part, to the acceleration of tumorigenesis.

Discussion

We have shown an opposite role for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma, providing the first evidence for a specific role of PARP-2 in supporting c-Myc-driven tumorigenesis. A key finding of our study is that loss of PARP-2 delays tumor onset and prolongs survival in $E\mu$ -Myc transgenic mice, whereas loss of PARP-1 accelerates tumorigenesis. In the $E\mu$ -Myc mouse model, overexpression of c-Myc in the B-cell lineage leads to a rapid expansion of BM pre-B cells associated with additional mutations that prevent cell death, such as inactivation of ARF and p53, leading to tumor development.¹⁷⁻¹⁹ Our data indicate that PARP-2 deficiency, but not loss of PARP-1, prevents the expansion of the pre-B cell compartment in $E\mu$ -Myc mice without affecting their proliferation rate. On the contrary, pre-B cells deficient in PARP-2 show increased cell death, which might explain the protection to develop B-cell lymphoma.

$E\mu$ -Myc^{T/+}Parp-2^{-/-} mice are more sensitive to alkylating agent treatment than $E\mu$ -Myc^{T/+} control mice (supplemental Figure 10), in agreement with the role of PARP-2 in maintaining genome stability.^{1,21} Accordingly, we found that PARP-2 limits c-Myc-driven genomic instability.^{37,38} Of note, PARP-2 deficiency in Myc-overexpressing B cells results in DNA damage accumulation, mainly in replicating cells, as indicated by the accumulation of γ H2AX in S phase³⁹⁻⁴² and the increased phosphorylation of Chk1, indicative of an active replication stress-driven ATR response.³⁰ This signaling cascade is linked with a transcriptional activation of p53-dependent cytostatic and apoptotic signals to prevent tumorigenesis. Indeed, loss of proapoptotic genes directly (Puma)⁴³ or indirectly (Bim)⁴⁴ regulated by p53 has been shown to increase survival of B cells^{45,46} and accelerate cMyc-driven lymphomagenesis.⁴⁷⁻⁴⁹ The expression of p53-dependent apoptotic genes was modified in pre-B cells from $E\mu$ -Myc^{T/+}Parp-2^{-/-} mice compared with control cells, with upregulation of proapoptotic genes (Puma and Bim) and downregulation of anti-apoptotic genes (Bcl2), tipping the balance toward a proapoptotic state, which may be critical for preventing tumorigenesis. In fact, we found that the prevention of Myc-induced B-cell lymphoma by loss of PARP-2 was dependent on the presence of p53, in agreement with previous data showing a synergistic interaction between PARP-2 and p53 in tumor suppression.⁹ However, we cannot rule out a direct role of PARP-2 in transcription regulation.⁵⁰ Indeed, PARP-2, but not PARP-1, has been shown to be a critical component in the androgen receptor transcriptional complex by interacting with FOXA1 favoring prostate cancer development, suggesting that selective inhibition of PARP-2 could be a therapeutic approach to treat prostate cancer.³²

Replication stress, a major driver of genomic instability mediated by c-Myc,⁵¹ is exacerbated by PARP-2 deficiency, but not by

loss of PARP-1. Of note, a critical role of PARP-2, but not PARP-1, in limiting replication stress has previously been noted in another model of high proliferative index as erythropoiesis.¹¹ Stalled replication forks, the major source of genome instability in proliferating cells,⁵² contain extensive single-strand DNA (ssDNA), which needs to be protected by the binding of RPA.⁵³ Interestingly, it has been reported that ssDNA breaks trigger the recruitment of PARP-2, and its specific activation leads to the subsequent recruitment of RPA.⁵⁴ Accordingly, PARP-2 deficiency in highly proliferating $E\mu$ -Myc cells might impair RPA-mediated ssDNA protection required for replication fork stabilization.⁵³ Moreover, PARP-2 is also required for stabilizing replication forks through stabilization of RAD51,⁵⁵ which is required for replication fork reversal to facilitate fork repair.⁵³

Inflammation has been associated with initiation of tumor development, and increased levels of inflammatory mediators have been linked to poor prognosis.⁵⁶ Remarkably, PARP-1 deficiency accelerates c-Myc-driven tumorigenesis associated with enrichment in inflammatory response pathways, including upregulation of cytokine and chemokine genes. This finding was somewhat unexpected, because previous work has shown that PARP-1 contributes to inflammation mainly through its modulatory function on the proinflammatory transcription factor NF- κ B.⁵⁷ However, PARP-1 does not always correlate with upregulation of NF- κ B target genes. Indeed, silencing and enhancing transcription of NF- κ B target inflammatory genes by PARP-1 have been previously described,⁵⁸ suggesting that the effect of PARP-1 on the NF- κ B-dependent inflammatory gene expression may be dependent on the tissue and development stage.⁵⁷ Moreover, a recent report showed that PARP-1 promotes inflammation-driven colorectal tumor progression.⁵⁹

Additional events associated with the acceleration of tumorigenesis in PARP-1-deficient $E\mu$ -Myc mice could involve immunosuppressive mechanisms, including upregulation of the suppressive cytokine Tgfb1⁶⁰ and increased levels of Tregs. Of note, Tregs impaired immune response to tumors⁶¹ and have been demonstrated to play a critical role in suppressing antitumor response in endogenous B-cell lymphoma.³³ Altogether, our data suggest that PARP-1 affects cross-talk between the tumor cells and their microenvironment, with the net effect of suppressing tumorigenesis.

Currently, there is great interest in the use of PARP inhibitors for the treatment of different types of cancer, including diffuse large B-cell lymphoma.⁶² However, none of these inhibitors is specific, and all of them inhibit both PARP-1 and PARP-2. However, our data indicate opposing roles of these 2 proteins in the progression of tumors driven by the c-Myc oncogene, with the inactivation of PARP-2 having a clear protective effect and PARP-1 ablation benefiting tumor progression. Collectively, these findings have potentially significant therapeutic implications, highlighting the importance of developing selective PARP-2 inhibitors to treat c-Myc-driven tumors.

Acknowledgments

The authors thank Raul Gomez-Riera for assistance with microscopic analysis, María Luisa Toribio for providing the HRSIN-ICN1 plasmid, Jessica Gonzalez for technical assistance, and the Flow Cytometry

Unit and the Genomics Unit at the Centre for Genomic Regulation for assistance with Aseqq at the Barcelona Biomedical Research Park.

The J.Y. laboratory is funded by the Spanish Ministerio de Economía, Industria y Competitividad (grant SAF2017-83565-R), Spanish Ministerio de Ciencia e Innovación (grant PID2020-112526RB-I00), and Fundación Científica de la Asociación Española Contra el Cáncer (grant PROYEI6018YÉLA). Work in the J.E.S. laboratory is supported by a core grant to the Laboratory of Molecular Biology from the Medical Research Council (U105178808). The F.D. laboratory is supported by a Laboratory of Excellence grant (ANR-10-LABX-0034_Medalis) to Strasbourg University, Centre National de la Recherche Scientifique. The P.N. laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness/Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (FEDER; PI17/00199 and PI20/00625) and the Generalitat de Catalunya (2017-SGR-225). The P.M. laboratory acknowledges support from Centres de Recerca de Catalunya/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the Spanish Ministry of Economy and Competitiveness (grant SAF-2019-108160-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (grant LCF/PR/HR19/52160011), and the German Josep Carreras Leukämie Stiftung. Work at the G.R. and P.M. laboratories are cofinanced by the European Regional Development Fund through the Interreg V-A Spain-France-Andorra Program (project PROTEOblood; grant EFA360/19). The O.F.-C. laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTI2018-102204-B-I00; cofinanced with European FEDER funds) and the European Research Council (ERC-617840). T.V.-H. was supported by a Marie Skłodowska Curie fellowship (GA792923). The A.B. laboratory is supported by the Spanish Ministry of Economy and Competitiveness (grant PID2019-104695RB-I00).

Authorship

Contribution: M.A.G.-C. and N.L. contributed to generation and characterization of the mouse models and B-cell studies; S.B. carried out

bioinformatic analysis; C.M. carried out pathology experiments; J.M.-C. contributed to generation of mouse models; M.M. and O.F.-C. contributed to characterization of mouse models; T.V.-H., V.G.-H., P.M., and A.B. contributed to generation and characterization of an acute T lymphocyte leukemia mouse model; C.A. provided technical assistance; R.G., L.C., G.R., and F.D. provided reagents and biologic resources; G.G. and J.E.S. contributed to planning replication stress studies and editing the manuscript. P.N. designed experiments; J.Y. planned, designed, and performed experiments and wrote the manuscript; and all authors discussed the results and commented on the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: José Yélamos, Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona Biomedical Research Park, C/Dr. Aiguader, 88, 08003-Barcelona, Spain; e-mail: jyelamos@imim.es.

Footnotes

Submitted 7 June 2021; accepted 30 July 2021; prepublished online on *Blood* First Edition 6 August 2021. DOI 10.1182/blood.2021012805.

*M.A.G.-C. and N.L. contributed equally to this study.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

REFERENCES

1. Yelamos J, Farres J, Llacuna L, Ampurdanes C, Martín-Caballero J. PARP-1 and PARP-2: new players in tumour development. *Am J Cancer Res*. 2011;1(3):328-346.
2. Suskiewicz MJ, Palazzo L, Hughes R, Ahel I. Progress and outlook in studying the substrate specificities of PARPs and related enzymes. *FEBS J*. 2021;288(7):2131-2142.
3. Bai P. Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. *Mol Cell*. 2015;58(6):947-958.
4. Azam K, Smith S. Nuclear PARPs and genome integrity. *Genes Dev*. 2020;34(5-6):285-301.
5. Slade D. PARP and PARG inhibitors in cancer treatment. *Genes Dev*. 2020;34(5-6):360-394.
6. Pilger D, Seymour LW, Jackson SP. Interfaces between cellular responses to DNA damage and cancer immunotherapy. *Genes Dev*. 2021;35(9-10):602-618.
7. Dantzer F, Mark M, Quenet D, et al. Poly(ADP-ribose) polymerase-2 contributes to the fidelity of male meiosis I and spermiogenesis. *Proc Natl Acad Sci USA*. 2006;103(40):14854-14859.
8. Yélamos J, Monreal Y, Saenz L, et al. PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes. *EMBO J*. 2006;25(18):4350-4360.
9. Nicolás L, Martínez C, Baró C, et al. Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice. *Oncogene*. 2010;29(19):2877-2883.
10. Farrés J, Martín-Caballero J, Martínez C, et al. Parp-2 is required to maintain hematopoiesis following sublethal γ -irradiation in mice. *Blood*. 2013;122(1):44-54.
11. Farrés J, Llacuna L, Martín-Caballero J, et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. *Cell Death Differ*. 2015;22(7):1144-1157.
12. Murga M, Bunting S, Montaña MF, et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. *Nat Genet*. 2009;41(8):891-898.
13. Gaillard H, García-Muse T, Aguilera A. Replication stress and cancer. *Nat Rev Cancer*. 2015;15(5):276-289.
14. Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. *Annu Rev Pathol*. 2015;10:425-448.
15. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *J Clin Oncol*. 2012;30(28):3452-3459.
16. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. *Br J Haematol*. 2010;149(4):484-497.
17. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. *J Exp Med*. 1988;167(2):353-371.
18. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. *Genes Dev*. 1999;13(20):2658-2669.
19. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. *Nature*. 1990;348(6299):331-333.
20. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. *Proc Natl Acad Sci USA*. 1997;94(14):7303-7307.
21. Ménissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. *EMBO J*. 2003;22(9):2255-2263.
22. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin

- enhancers induces lymphoid malignancy in transgenic mice. *Nature*. 1985; 318(6046):533-538.
23. Galindo-Campos MA, Bedora-Faure M, Farrés J, et al. Coordinated signals from the DNA repair enzymes PARP-1 and PARP-2 promotes B-cell development and function. *Cell Death Differ*. 2019;26(12):2667-2681.
 24. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. *Cell*. 1986;47(1):11-18.
 25. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. *DNA Repair (Amst)*. 2004;3(8-9):959-967.
 26. Toledo LI, Murga M, Zur R, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. *Nat Struct Mol Biol*. 2011;18(6):721-727.
 27. Syljuåsen RG, Sørensen CS, Hansen LT, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. *Mol Cell Biol*. 2005;25(9):3553-3562.
 28. Murga M, Campaner S, Lopez-Contreras AJ, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. *Nat Struct Mol Biol*. 2011; 18(12):1331-1335.
 29. Liu S, Opiyo SO, Manthey K, et al. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress. *Nucleic Acids Res*. 2012;40(21):10780-10794.
 30. López-Contreras AJ, Fernandez-Capetillo O. The ATR barrier to replication-born DNA damage. *DNA Repair (Amst)*. 2010; 9(12):1249-1255.
 31. Michalak EM, Jansen ES, Haplo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. *Cell Death Differ*. 2009;16(5):684-696.
 32. Gui B, Gui F, Takai T, et al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. *Proc Natl Acad Sci USA*. 2019;116(29):14573-14582.
 33. Ahmetlić F, Riedel T, Hömberg N, et al. Regulatory T cells in an endogenous mouse lymphoma recognize specific antigen peptides and contribute to immune escape. *Cancer Immunol Res*. 2019;7(4):600-608.
 34. Nasta F, Laudisi F, Sambucci M, Rosado MM, Pioli C. Increased Foxp3+ regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency. *J Immunol*. 2010;184(7):3470-3477.
 35. Navarro J, Gozalbo-López B, Méndez AC, et al. PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas. *Sci Rep*. 2017; 7:41962.
 36. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF- β induction of transcription factor Foxp3. *J Exp Med*. 2003;198(12):1875-1886.
 37. Zuzyk A, Mai S. c-MYC-induced genomic instability. *Cold Spring Harb Perspect Med*. 2014;4(4):a014373.
 38. Kumari A, Folk WP, Sakamuro D. The dual roles of MYC in genomic instability and cancer chemoresistance. *Genes (Basel)*. 2017;8(6):158.
 39. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. *J Biol Chem*. 2001;276(51):47759-47762.
 40. Furuta T, Takemura H, Liao Z-Y, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. *J Biol Chem*. 2003;278(22):20303-20312.
 41. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. *Mol Cancer Ther*. 2007;6(4):1239-1248.
 42. Gagou ME, Zuazua-Villar P, Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. *Mol Biol Cell*. 2010; 21(5):739-752.
 43. Fischer M. Census and evaluation of p53 target genes. *Oncogene*. 2017; 36(28):3943-3956.
 44. Haplo L, Cragg MS, Phipson B, et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. *Blood*. 2010;116(24):5256-5267.
 45. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. *Science*. 1999;286(5445):1735-1738.
 46. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. *Science*. 2003;302(5647):1036-1038.
 47. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. *Proc Natl Acad Sci USA*. 2004; 101(16):6164-6169.
 48. Garrison SP, Jeffers JR, Yang C, et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. *Mol Cell Biol*. 2008;28(17):5391-5402.
 49. Valente LJ, Grabow S, Vandenberg CJ, Strasser A, Janic A. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. *Oncogene*. 2016;35(29):3866-3871.
 50. Szántó M, Brunyánszki A, Kiss B, et al. Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein. *Cell Mol Life Sci*. 2012;69(24):4079-4092.
 51. Dominguez-Sola D, Gautier J. MYC and the control of DNA replication. *Cold Spring Harb Perspect Med*. 2014;4(6):a014423.
 52. Toledo L, Neelsen KJ, Lukas J. Replication catastrophe: when a checkpoint fails because of exhaustion. *Mol Cell*. 2017; 66(6):735-749.
 53. Liao H, Ji F, Helleday T, Ying S. Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments. *EMBO Rep*. 2018; 19(9):e46263.
 54. Miyoshi T, Makino T, Moran JV. Poly(ADP-ribose) polymerase 2 recruits replication protein A to sites of LINE-1 integration to facilitate retrotransposition. *Mol Cell*. 2019; 75(6):1286-1298.e12.
 55. Ronson GE, Piberger AL, Higgs MR, et al. PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. *Nat Commun*. 2018;9(1):746.
 56. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420(6917):860-867.
 57. Fehr AR, Singh SA, Kerr CM, Mukai S, Higashi H, Aikawa M. The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions. *Genes Dev*. 2020;34(5-6):341-359.
 58. Carrillo A, Monreal Y, Ramírez P, et al. Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. *Nucleic Acids Res*. 2004;32(2):757-766.
 59. Dörsam B, Seiwert N, Foersch S, et al. PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. *Proc Natl Acad Sci USA*. 2018;115(17):E4061-E4070.
 60. Sheng J, Chen W, Zhu HJ. The immune suppressive function of transforming growth factor- β (TGF- β) in human diseases. *Growth Factors*. 2015;33(2):92-101.
 61. Glasner A, Plitas G. Tumor resident regulatory T cells. *Semin Immunol*. 2021;24: 101476.
 62. Parvin S, Ramirez-Labrada A, Aumann S, et al. LMO2 confers synthetic lethality to PARP inhibition in DLBCL. *Cancer Cell*. 2019; 36(3):237-249.e6.